Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER3 | P43115 | 18/20 | 0.65 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2890763 | 1.00 | PTGER3 (0.65) | PTGER3CTRB1PTGER4CHRM5 | |
| SCHEMBL1137339 | 0.87 | PTGER3 (0.66) | PTGER3CTRB1PTGER4 | |
| SCHEMBL1137334 | 0.87 | PTGER3 (0.66) | PTGER3CTRB1PTGER4 | |
| SCHEMBL5324748 | 0.83 | PTGER3 (0.49) | PTGER3PTGER4 | |
| SCHEMBL5324752 | 0.83 | PTGER3 (0.49) | PTGER3PTGER4 | |
| SCHEMBL12862610 | 0.78 | PTGER3 (0.67) | PTGER3 | |
| SCHEMBL1137514 | 0.77 | PTGER3 (0.64) | PTGER3 | |
| SCHEMBL1137513 | 0.77 | PTGER3 (0.64) | PTGER3 | |
| SCHEMBL13020380 | 0.77 | HDAC3 (0.60) | — | |
| SCHEMBL2890111 | 0.72 | PTGER3 (0.58) | PTGER3CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7714017-B2 | for prostaglandin-mediated disorders; (E)-3-[1-(2,4-Dichloro-benzyl)-3,3-bis-hydroxymethyl-2-oxo-2,3-dihydro-1H-indol-7-yl]-acrylic acid | DECODE GENETICS, EHF (IS) | 2010-05-11 | — | — | US | disclosed |
| US-20060142355-A1 | Carboxylic acid peri-substituted bicyclics for occlusive artery disease | DECODE CHEMISTRY, INC. (US) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142355-A1 | Carboxylic acid peri-substituted bicyclics for occlusive artery disease | PTGIS, PTGIR, PTGDR | PTGER3 19/4885CTRB1 1710/4885PTGER4 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.